Phenoxodiol (PXD) has been in trials for quite some time, although the
(US) FDA approved it in 2001 for "fast-track" to approval status.

Marshall Edwards, Inc., a US company, has been involved in the process
under license from the Australian developer, Novogen.

The diseases being studied for tx are ovarian, renal, cervical and
prostate cancers.

On May 19, 2006, the company released its newsletter, outlining the
current status of various trials.

On page four, there is a brief mention of the fact that the Stage II
clinical trial of PXD in tx of PCa has been completed and that Stage III
trials are being designed. They expect to make an announcement in 2006.

Recruitment for ovarian cancer tx is now proceeding in the US at
Yale-New Haven Hospital in association with docetaxol's manufacturer,
Sanofi-Aventis. One wonders whether a similar effect might be achieved
in tx of PCa.

The newsletter can be found (if this works right) at:
http://www.marshalledwardsinc.com/pdf/MSHL%20Newsletter.pdf
In the alternative, one can go to the company home page and use the link.

PXD acts as a chemosensitizer. Early on, I read that it reduced the
required dosage of chemo agent by a huge amount. I do not know the
present status, but if that proves out it will IMO be little short of
miraculous.

Regards,

Steve J

"Do not go where the path may lead, go instead where there is no path
and leave a trail."
-- Ralph Waldo Emerson